Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.

Abbott also is a buy for its dividend strength. As a Dividend King it's raised its dividend for more than 50 consecutive ...

Shares of Eli Lilly & Co. were headed for their worst day ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...